The Biotechnology Industry Organization (BIO) will be holding its annual BIO International Convention next week in Boston, MA. Founded in 1993, BIO is a nonprofit association seeking supportive biotechnology policies on behalf of more than 1,100 biotechnology companies, state and international affiliates, and related organizations, as well as providing business development services for many emerging biotech companies.
As part of the Convention, more than 1,800 biotech companies, organizations, and institutions are expected to participate in the BIO Exhibition. Patent Docs authors Donald Zuhn and Kevin Noonan, and contributors Sherri Oslick, James DeGiulio, Andrew Williams, and Kwame Mensah will also be attending BIO as part of the MBHB contingent, and will be participating in BIO's blogger network throughout the week. Patent Docs readers who may be attending BIO this week are encouraged to stop by Booth 1335 - Hall A to meet the Docs, at the times indicated below, and talk a little biotech patent law.
Monday, June 18
12:00 - 2:30 pm -- Sherri Oslick
2:30 - 5:00 pm -- James DeGiulio
Tuesday, June 19
10:00 am - 12:00 pm -- Donald Zuhn & Kwame Mensah
12:00 - 2:00 pm -- Kwame Mensah
2:00 - 4:00 pm -- Donald Zuhn
4:00 - 6:30 pm -- Sherri Oslick & James DeGiulio
Wednesday, June 20
10:00 am - 12:00 pm -- James DeGiulio
12:00 - 2:00 pm -- Sherri Oslick, James DeGiulio & Kwame Mensah
3:30 - 5:00 pm -- Donald Zuhn & Andrew Williams
Thursday, June 21
10:00 - 11:30 am -- Donald Zuhn & Kevin Noonan
11:30 am - 1:00 pm -- Kevin Noonan & Andrew Williams
The Convention also offers more than 125 breakout sessions. A program listing all of the sessions can be found here. Among the sessions that may be of interest to Patent Docs readers are:
Monday, June 18
• Access to and Uptake of Biosimilars: The European Experience -- 10:00 - 11:30 am
• IP Challenges to Personalized Medicine & Diagnostics -- 2:00 - 3:30 pm
• The New World: Post-Grant Review in the United States -- What Can We Learn from Past Experiences in Europe, Japan, India and Australia -- 2:00 - 3:30 pm
• Cross–border Intellectual Property Challenges in Strategic Research Collaboration between Canada and California (Cancer Stem Cell Case Study) -- 3:00 - 3:45 pm
• Successful IP Strategies for Biotech Platform Technologies -- 3:45 – 5:00 pm
Tuesday, June 19
• Options for Generic Biotech Crops: An "Accord" on Responsibility and Data Compensation for Expiring Patents and Overseas Approvals -- 8:30 - 9:45 am
• Recent Developments in Patentability: Prometheus, Myriad, Classen and the Patentability of Diagnostic Methods -- 8:30 - 9:45 am
• Beyond Borders: Ernst & Young’s Annual Biotechnology Industry Report (Super Session) -- 10:00 - 11:30 am
• Prior User Rights and Trade Secrets: A New IP Option Replacing Patents to Secure Freedom-to-Operate for Internally-Used Innovations in Biotechnology -- 2:00 – 3:30 pm
• Burrill State-of-the-Industry Report (Super Session) - 2:00 - 3:30 pm
• FDA Town Hall -- 2:00 – 3:30 pm
• International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard (Super Session) -- 3:45 - 5:15 pm
Wednesday, June 20
• Patenting Under the America Invents Act in Comparison with European Patent Practice -- 10:00 - 11:30 am
• IP Issues Affecting Biomarker Diagnostics and Personalized Medicine -- 2:00 - 3:30 pm
Thursday, June 21
• Enactment of the Leahy-Smith America Invents Act 2011 (AIA): How Changes to Patent Law in the United States Will Impact Commercialization and Technology Transfer Offices -- 8:30 - 9:45 am
• Challenges and Opportunities of Protecting and Managing IP Assets in Emerging Markets -- 10:00 - 11:30 am
In addition, the Docs will be attending the MBHB reception at Black Rose Pub, 160 State Street, from 9:00 pm to 1:00 am on Tuesday, June 19. Additional information about the reception, including invitations for the event, can be picked up at the MBHB booth (Booth 1335 - Hall A) on Monday or Tuesday.
Comments